The U.S. Centers for Disease Control and Prevention (CDC) has updated its recommendations regarding who should receive the vaccine for respiratory syncytial virus (RSV), a common respiratory virus that usually causes mild symptoms but can lead to severe health complications in certain vulnerable populations.
On June 26, the CDC announced that it now strongly recommends the RSV vaccine for two specific groups: adults aged 75 and older and adults aged 60 to 74 who have chronic health conditions that put them at higher risk for severe illness.
This new guidance marks a significant change from the previous guidelines issued in the fall of the previous year. At that time, the CDC suggested that people aged 60 and older could consider receiving the RSV vaccine after consulting with their healthcare provider. The revision indicated a more targeted approach to protect those at the highest risk of serious illness from RSV during the upcoming fall virus season.
Increased Focus on Nursing Home Residents
Dr. Mandy Cohen, Director of the CDC, emphasized the importance of RSV vaccination for adults living in nursing homes, highlighting their heightened vulnerability to severe illness.
“It appears the CDC updated the recommendation to ensure those at highest risk for developing severe illness from RSV are being prioritized for vaccination,” explained Krutika Kuppalli, MD, a spokesperson for the Infectious Diseases Society of America (IDSA) and former medical officer at the World Health Organization (WHO).
The CDC also clarified that individuals who have already received an RSV vaccine do not need another dose. Unlike the annual flu vaccine, the RSV vaccine does not require yearly administration. Therefore, once vaccinated, individuals are expected to have long-lasting protection without the need for an annual booster.
Why the CDC Updated Its Guidelines
The change in vaccination criteria reflects the CDC’s focus on protecting the most vulnerable populations. The federal health agency aims to ensure that those at the highest risk of severe RSV complications, such as older adults and those with chronic health conditions, are prioritized for vaccination.
Despite the approval of the first RSV vaccines over a year ago by the U.S. Food and Drug Administration (FDA), vaccination rates remain relatively low. According to the CDC’s latest data, only about 24% of adults aged 60 and over had been vaccinated by spring 2024.
The previous guidelines left the decision to get vaccinated up to individuals and their healthcare providers, leading to some ambiguity. “The initial recommendation was not clear about who should get the vaccine, so this may affect uptake,” says Dr. Kuppalli.
By clearly identifying high-risk groups, the CDC hopes to streamline the vaccination process and increase uptake among those most likely to benefit from the vaccine. However, there is concern that this narrower focus may reduce overall immunization rates by limiting the pool of eligible recipients.
The Importance of RSV Vaccination
RSV is a highly contagious virus that typically causes mild, cold-like symptoms in adults, such as a runny nose, sore throat, cough and headache. However, for certain individuals, particularly those with weakened immune systems or pre-existing health conditions, RSV can lead to severe complications like rapid breathing, fever, and pneumonia.
The federal government estimates that RSV results in 60,000 to 160,000 hospitalizations among adults aged 65 and older annually. Furthermore, about 6,000 to 10,000 deaths each year are attributed to RSV-related lower respiratory tract disease in this age group.
The vaccine is especially important for older adults with chronic health conditions such as chronic obstructive pulmonary disease (COPD), asthma, congestive heart failure, and coronary artery disease. For these individuals, the RSV vaccine can be a critical tool in preventing severe disease outcomes, potentially reducing the need for hospitalization and the risk of death.
RSV Vaccine Options and Effectiveness
Currently, three are three RSV vaccines available: Arexvy (GSK), Abrysyo (Pfizer), and mRESVIA (Moderna). Each of these vaccines has been shown to be effective, although their efficacy diminishes over time.
In a large-stage clinical trial of Arexvy in people aged 60 and older, a single dose of the vaccine reduced the incidence of symptomatic RSV lower respiratory tract disease by over 82% during the first RSV season after vaccination, compared to a placebo. This effectiveness dropped to 56% during the second RSV season.
Similarly, Abrysvo demonstrated a strong protective effect in a comparable trial, reducing RSV lower respiratory tract disease with three or more symptoms by nearly 89% during the first RSV season. The efficacy declined to around 79% during a partial second RSV season.
Moderna’s mRESVIA, the most recent RSV vaccine approved by the FDA in May, showed an efficacy rate of between 82% and 84% in the first RSV season. However, data presented on June 26 revealed that the effectiveness of the Moderna vaccine dropped to 50% after 18 months.
These findings indicate that while the RSV vaccines are effective in the short term, their protective benefits may wane over time.
Evaluating Potential Risks: Guillain-Barré Syndrome
As with any vaccine, there are potential risks associated with RSV vaccination. The CDC is currently evaluating the risk of Guillain-Barré syndrome (GBS) in older adults following RSV vaccination.
GBS is a rare neurological disorder that can occur after immunization, causing muscle weakness and, in severe cases, paralysis. However, most people diagnosed with GBS can make a full recovery.
This ongoing evaluation is part of the CDC’s commitment to ensuring that vaccines are both safe and effective, particularly for the populations most in need of protection.
Balancing Benefits and Risks
The CDC’s revised guidelines for RSV vaccination reflect an effort to balance the benefits of protecting high-risk populations against the potential risks. By prioritizing adults aged 75 an older, as well as those aged 60 to 74 with underlying health conditions, the agency aims to target those most likely to experience severe outcomes from RSV infection. While the updated recommendations may narrow the scope of vaccination, they seek to provide clarity and focus in the ongoing effort to reduce RSV-related illness and death.
The evolution of these guidelines underscores the dynamic nature of public health strategies, which must adapt to emerging data and changing circumstances.
As more information becomes available, particularly regarding vaccine efficacy and safety, the CDC may continue to refine its recommendations to best protect public health.
Recommended For You
